General Information of Drug (ID: DMHMC19)

Drug Name
CD137 CAR-T Cell Drug Info
Indication
Disease Entry ICD 11 Status REF
Acute lymphoblastic leukaemia 2A85 Phase 1/2 [1]
B-cell lymphoma 2A86 Phase 1/2 [1]
Cross-matching ID
TTD Drug ID
DMHMC19

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Urelumab DM6RTVG B-cell non-hodgkin lymphoma 2B33.5 Phase 2 [2]
Anti-CD137 DMHVZ27 Solid tumour/cancer 2A00-2F9Z Phase 2 [3]
MG7-CART DME6PB0 Acute myeloid leukaemia 2A60 Phase 1/2 [4]
NM21-1480 DMDNJP5 Advanced solid tumour 2A00-2F9Z Phase 1/2 [5]
ADG106 DM87H0S Non-hodgkin lymphoma 2B33.5 Phase 1/2 [6]
CD28 and CD137 CAR-T Cells DMFGQXB Acute lymphoblastic leukaemia 2A85 Phase 1 [7]
MCLA-145 DM8CGUV Lymphoma 2A80-2A86 Phase 1 [8]
GEN1046 DMEWRNZ Solid tumour/cancer 2A00-2F9Z Phase 1 [9]
INBRX-105 DM2FH10 Solid tumour/cancer 2A00-2F9Z Phase 1 [10]
GEN1042 DMNP6T3 Solid tumour/cancer 2A00-2F9Z Phase 1 [9]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Co-stimulatory molecule 4-1BB (CD137) TTPW9LJ TNR9_HUMAN CAR-T-Cell-Therapy [1]

References

1 ClinicalTrials.gov (NCT02965092) CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1878).
4 ClinicalTrials.gov (NCT02862704) A Study of MG7 Redirected Autologous T Cells for Advanced MG7 Positive Liver Metastases(MG7-CART)
5 Clinical pipeline report, company report or official report of Numab Therapeutics.
6 Clinical pipeline report, company report or official report of Adagene.
7 ClinicalTrials.gov (NCT02186860) Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With Acute Lymphoblastic Leukemia
8 Clinical pipeline report, company report or official report of Merus.
9 Clinical pipeline report, company report or official report of Genmab.
10 Clinical pipeline report, company report or official report of Inhibrx.